Compare Novartis AG (NVS) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs TeraWulf Inc — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while TeraWulf Inc trades at $13.98 (market cap $7.19B). The key difference: Novartis AG is far larger — about 38.1× TeraWulf Inc's market cap, and Novartis AG pays a 3.31% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and TeraWulf Inc for 17 Days on average.
| NVS | WULF | |
|---|---|---|
Market Cap | $274.00B | $7.19B |
Volume | 1,852,137 | 27,440,950 |
Sector | Health | Financials |
52-Week High | $168.62 | $28.98 |
52-Week Low | $121.80 | $10.99 |
Typical Hold Time | 82 Days | 17 Days |
Enterprise Value | $315.32B | $9.80B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
WULF trades at $14.40, down 3.81% on the day, amid a volatile period for AI infrastructure stocks. The company shows strong analyst support with 14 buy ratings and a consensus price target of $34.92, but fundamentals reveal challenges: revenue of $168.46M in 2025 was overshadowed by a net loss of -$661.42M, resulting in negative profit margins. Recent news highlights the company's pivot to AI data center hosting, with UBS initiating bullish coverage citing constrained compute supply (UBS, September 23, 2026).
The outlook is bifurcated: analyst optimism contrasts with weak profitability and bearish technical signals. Investment opportunity lies in the AI hosting transition, but risks include persistent losses, high debt-to-asset ratio of 78.84%, and sector volatility. The stock's current price near key support at $14 suggests cautious sentiment despite long-term growth potential in AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
